瑞格列奈、诺和灵30R联合使用对磺脲类药物继发失效2型糖尿病患者临床治疗效果分析

Analysis of Clinical Effect of Repaglinide, Novolin 30R in Treatment of Patients with Sulphonylurea Secondary Failure Type 2 Diabetes

目的探究瑞格列奈、诺和灵30R联合使用对磺脲类药物继发失效2型糖尿病患者的效果。方法针对40例磺脲类药物继发失效2型糖尿病患者实施诺和灵30R治疗(对照组),针对另外40例患者使用瑞格列奈、诺和灵30R联合治疗(观察组),比较两组患者的干预效果,两组患者均为该院2015年4月—2017年1月间收治。结果两组患者血糖水平、糖化血红蛋白水平治疗前差异无统计学意义,而经过分组治疗后观察组患者的情况改善更加明显,其中观察组患者的餐后2 h血糖为(9.31±2.13)mmol/L,而对照组患者为(12.21±8.35)mmol/L,组间比较差异有统计学意义(P<0.05)。结论瑞格列奈、诺和灵30R对磺脲类药物继发失效2型糖尿病患者治疗,无论采取单纯用药或联合用药的方法均能够对患者起到相应的治疗效果,但是瑞格列奈、诺和灵30R联合用药相对于诺和灵30R单纯治疗而言,能够有效控制患者血糖,因此值得临床优先选择。

Objective To study the clinical effect of repaglinide, novolin 30R in treatment of patients with sulphonylurea secondary failure type 2 diabetes. Methods 40 cases of patients in the control group were treated with novolin 30R, while 40 cases of patients in the observation group were treated with repaglinide, novolin 30R, and the intervention effect of the two groups was compared, and both groups were admitted from April 2015 to January 2017. Results There were no obvious differences in the blood glucose level and glycosylated hemoglobin between the two groups, and the improvement in the observation group after treatment was more obvious than that in the control group, and the postprandial 2 h blood glucose in the observation group and in the control group was respectively（9.31±2.13）mmol/L and（12.21±8.35）mmol/L, and the difference was statistically significant（P〈0.05）. Conclusion The single medication and combined medication of repaglinide and novolin 30R can obtain the effect, but the combined medication can more effectively control the blood glucose than that of single medication, therefore, it is worth first choice in clinic.